Reports
Global PD-1 and PD-L1 Inhibitors Market: By Type: PD-1 Inhibitors, PD-L1 Inhibitors; By Applications: Hodgkin Lymphoma, Kidney Cancer, Melanoma, Non-small Cell Lung Cancer, Others; By End User; Regional Analysis; Historical Market and Forecast (2018-2028); Market Dynamics; Competitive Landscape; Industry Events and Developments
Global PD-1 and PD-L1 Inhibitors Market Outlook
The global PD-1 and PD-L1 inhibitors market stood at a value of around USD 30.3 billion in 2021. The market is further expected to grow at a CAGR of 17.50% in the forecast period of 2023-2028 to attain a value of USD 80.9 billion by 2027.
PD-1 Inhibitors to Account for a Significant Market Share of the Global PD-1 and PD-L1 Inhibitors Industry
Based on type, the PD-1 inhibitors segment is predicted to hold a significant market share in the PD-1 and PD-L1 inhibitors industry. This can be attributed to the growing research and development activities, along with the increased usage of these inhibitors such as Nivolumab and Pembrolizumab. Moreover, the increased usability of these medicines for treating various types of cancers is projected to positively impact the market growth in the forecast period.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
North America to Offer Significant Growth Opportunities to the Global PD-1 and PD-L1 Inhibitors Industry
North America is predicted to possess a significant share of the PD-1 and PD-L1 inhibitors industry in the forecast period. This can be attributed to the rising incidences of cancer in the region, with cancer being the prominent cause of death in Canada and the second most prevalent cause in the United States. In addition, the growing geriatric population is further adding to the market growth, owing to their increased susceptibility to chronic illnesses. These factors are projected to aid the market growth in the coming years.
PD-1 and PD-L1 Inhibitors: Market Segmentation
PD-1 (programmed cell death protein 1) and PD-L1 (programmed cell death ligand 1) inhibitors refer to a group of checkpoint inhibitor anti-cancer drugs that are used as the front-line treatment for various cancer types. These help stop the activity of PD-1 and PD-L1 proteins that are present on the surface of cells. PD-1 inhibitors are transmitted intravenously.
By type, the market is divided into:
- PD-1 Inhibitors
- PD-L1 Inhibitors
On the basis of application, the market can be segmented into:
- Hodgkin Lymphoma
- Kidney Cancer
- Melanoma
- Non-Small Cell Lung Cancer
- Others
Based on end user, the market can be categorised into:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Rising Incidences of Cancer to Augment the Growth of the Global PD-1 and PD-L1 Inhibitors Industry
The growing incidences of cancer are projected to catalyse the market growth in the forecast period. According to the WHO statistics, cancer is one of the leading causes of death worldwide, with around 10 million casualties reported in 2020. The numbers are predicted to increase over time, as many patients were unable to attain proper care and medical treatment, especially in 2020 amid the rampant spread of the COVID-19 virus worldwide. Among these, the most commonly found cancer is breast cancer. In 2020, an estimated 2.3 million women were diagnosed with breast cancer. Observing the growing prevalence of cancer cases globally, governments and international organisations are increasingly devising strategies and conceptualising initiatives to raise funds and awareness about cancer and its potential prevention. Additionally, there has been an increase in investments to support the pharmaceutical industry and improve healthcare facilities. These factors are projected to catalyse the market growth in the forecast period.
Key Industry Players in the Global PD-1 and PD-L1 Inhibitors Market
The report gives a detailed analysis of the following key players in the global PD-1 and PD-L1 inhibitors market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
- F. Hoffmann-La Roche AG
- Sanofi S.A.
- Amgen Inc.
- AstraZeneca PLC
- Pfizer Inc.
- Bristol-Myers Squibb Company
- Others
The comprehensive EMR report provides an in-depth assessment of the industry based on the Porter's five forces model and SWOT analysis.
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2018-2022 |
| Forecast Period | 2023-2028 |
| Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Type, Applications, End User, Region |
| Breakup by Type | PD-1 Inhibitors, PD-L1 Inhibitors |
| Breakup by Applications | Hodgkin Lymphoma, Kidney Cancer, Melanoma, Non-small Cell Lung Cancer, Others |
| Breakup by End User | Hospital Pharmacies, Retail Pharmacies, Online Pharmacies |
| Breakup by Region | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Market Dynamics | SWOT, Porter's Five Forces, Key Indicators for Price and Demand |
| Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
| Companies Covered | F. Hoffmann-La Roche AG, Sanofi S.A., Amgen Inc., AstraZeneca PLC, Pfizer Inc., Bristol-Myers Squibb Company, Others |
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Opportunities and Challenges in the Market
8 Global PD-1 and PD-L1 Inhibitors Market Analysis
8.1 Key Industry Highlights
8.2 Global PD-1 and PD-L1 Inhibitors Historical Market (2018-2022)
8.3 Global PD-1 and PD-L1 Inhibitors Market Forecast (2023-2028)
8.4 Global PD-1 and PD-L1 Inhibitors Market by Type
8.4.1 PD-1 Inhibitors
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2018-2022)
8.4.1.3 Forecast Trend (2023-2028)
8.4.2 PD-L1 Inhibitors
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2018-2022)
8.4.2.3 Forecast Trend (2023-2028)
8.5 Global PD-1 and PD-L1 Inhibitors Market by Applications
8.5.1 Hodgkin Lymphoma
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2018-2022)
8.5.1.3 Forecast Trend (2023-2028)
8.5.2 Kidney Cancer
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2018-2022)
8.5.2.3 Forecast Trend (2023-2028)
8.5.3 Melanoma
8.5.3.1 Market Share
8.5.3.2 Historical Trend (2018-2022)
8.5.3.3 Forecast Trend (2023-2028)
8.5.4 Non-small Cell Lung Cancer
8.5.4.1 Market Share
8.5.4.2 Historical Trend (2018-2022)
8.5.4.3 Forecast Trend (2023-2028)
8.5.5 Others
8.6 Global PD-1 and PD-L1 Inhibitors Market by End User
8.6.1 Hospital Pharmacies
8.6.1.1 Market Share
8.6.1.2 Historical Trend (2018-2022)
8.6.1.3 Forecast Trend (2023-2028)
8.6.2 Retail Pharmacies
8.6.2.1 Market Share
8.6.2.2 Historical Trend (2018-2022)
8.6.2.3 Forecast Trend (2023-2028)
8.6.3 Online Pharmacies
8.6.3.1 Market Share
8.6.3.2 Historical Trend (2018-2022)
8.6.3.3 Forecast Trend (2023-2028)
8.7 Global PD-1 and PD-L1 Inhibitors Market by Region
8.7.1 North America
8.7.1.1 Market Share
8.7.1.2 Historical Trend (2018-2022)
8.7.1.3 Forecast Trend (2023-2028)
8.7.2 Europe
8.7.2.1 Market Share
8.7.2.2 Historical Trend (2018-2022)
8.7.2.3 Forecast Trend (2023-2028)
8.7.3 Asia Pacific
8.7.3.1 Market Share
8.7.3.2 Historical Trend (2018-2022)
8.7.3.3 Forecast Trend (2023-2028)
8.7.4 Latin America
8.7.4.1 Market Share
8.7.4.2 Historical Trend (2018-2022)
8.7.4.3 Forecast Trend (2023-2028)
8.7.5 Middle East and Africa
8.7.5.1 Market Share
8.7.5.2 Historical Trend (2018-2022)
8.7.5.3 Forecast Trend (2023-2028)
9 North America PD-1 and PD-L1 Inhibitors Market Analysis
9.1 United States of America
9.1.1 Market Share
9.1.2 Historical Trend (2018-2022)
9.1.3 Forecast Trend (2023-2028)
9.2 Canada
9.2.1 Market Share
9.2.2 Historical Trend (2018-2022)
9.2.3 Forecast Trend (2023-2028)
10 Europe PD-1 and PD-L1 Inhibitors Market Analysis
10.1 United Kingdom
10.1.1 Market Share
10.1.2 Historical Trend (2018-2022)
10.1.3 Forecast Trend (2023-2028)
10.2 Germany
10.2.1 Market Share
10.2.2 Historical Trend (2018-2022)
10.2.3 Forecast Trend (2023-2028)
10.3 France
10.3.1 Market Share
10.3.2 Historical Trend (2018-2022)
10.3.3 Forecast Trend (2023-2028)
10.4 Italy
10.4.1 Market Share
10.4.2 Historical Trend (2018-2022)
10.4.3 Forecast Trend (2023-2028)
10.5 Others
11 Asia Pacific PD-1 and PD-L1 Inhibitors Market Analysis
11.1 China
11.1.1 Market Share
11.1.2 Historical Trend (2018-2022)
11.1.3 Forecast Trend (2023-2028)
11.2 Japan
11.2.1 Market Share
11.2.2 Historical Trend (2018-2022)
11.2.3 Forecast Trend (2023-2028)
11.3 India
11.3.1 Market Share
11.3.2 Historical Trend (2018-2022)
11.3.3 Forecast Trend (2023-2028)
11.4 ASEAN
11.4.1 Market Share
11.4.2 Historical Trend (2018-2022)
11.4.3 Forecast Trend (2023-2028)
11.5 Australia
11.5.1 Market Share
11.5.2 Historical Trend (2018-2022)
11.5.3 Forecast Trend (2023-2028)
11.6 Others
12 Latin America PD-1 and PD-L1 Inhibitors Market Analysis
12.1 Brazil
12.1.1 Market Share
12.1.2 Historical Trend (2018-2022)
12.1.3 Forecast Trend (2023-2028)
12.2 Argentina
12.2.1 Market Share
12.2.2 Historical Trend (2018-2022)
12.2.3 Forecast Trend (2023-2028)
12.3 Mexico
12.3.1 Market Share
12.3.2 Historical Trend (2018-2022)
12.3.3 Forecast Trend (2023-2028)
12.4 Others
13 Middle East and Africa PD-1 and PD-L1 Inhibitors Market Analysis
13.1 Saudi Arabia
13.1.1 Market Share
13.1.2 Historical Trend (2018-2022)
13.1.3 Forecast Trend (2023-2028)
13.2 United Arab Emirates
13.2.1 Market Share
13.2.2 Historical Trend (2018-2022)
13.2.3 Forecast Trend (2023-2028)
13.3 Nigeria
13.3.1 Market Share
13.3.2 Historical Trend (2018-2022)
13.3.3 Forecast Trend (2023-2028)
13.4 South Africa
13.4.1 Market Share
13.4.2 Historical Trend (2018-2022)
13.4.3 Forecast Trend (2023-2028)
13.5 Others
14 Market Dynamics
14.1 SWOT Analysis
14.1.1 Strengths
14.1.2 Weaknesses
14.1.3 Opportunities
14.1.4 Threats
14.2 Porter’s Five Forces Analysis
14.2.1 Supplier’s Power
14.2.2 Buyer’s Power
14.2.3 Threat of New Entrants
14.2.4 Degree of Rivalry
14.2.5 Threat of Substitutes
14.3 Key Indicators for Demand
14.4 Key Indicators for Price
15 Competitive Landscape
15.1 Market Structure
15.2 Company Profiles
15.2.1 F. Hoffmann-La Roche AG
15.2.1.1 Company Overview
15.2.1.2 Product Portfolio
15.2.1.3 Demographic Reach and Achievements
15.2.1.4 Certifications
15.2.2 Sanofi S.A.
15.2.2.1 Company Overview
15.2.2.2 Product Portfolio
15.2.2.3 Demographic Reach and Achievements
15.2.2.4 Certifications
15.2.3 Amgen Inc.
15.2.3.1 Company Overview
15.2.3.2 Product Portfolio
15.2.3.3 Demographic Reach and Achievements
15.2.3.4 Certifications
15.2.4 AstraZeneca PLC
15.2.4.1 Company Overview
15.2.4.2 Product Portfolio
15.2.4.3 Demographic Reach and Achievements
15.2.4.4 Certifications
15.2.5 Pfizer Inc.
15.2.5.1 Company Overview
15.2.5.2 Product Portfolio
15.2.5.3 Demographic Reach and Achievements
15.2.5.4 Certifications
15.2.6 Bristol-Myers Squibb Company
15.2.6.1 Company Overview
15.2.6.2 Product Portfolio
15.2.6.3 Demographic Reach and Achievements
15.2.6.4 Certifications
15.2.7 Others
16 Key Trends and Developments in the Market
List of Key Figures and Tables
1. Global PD-1 and PD-L1 Inhibitors Market: Key Industry Highlights, 2018 and 2028
2. Global PD-1 and PD-L1 Inhibitors Historical Market: Breakup by Type (USD Billion), 2018-2022
3. Global PD-1 and PD-L1 Inhibitors Market Forecast: Breakup by Type (USD Billion), 2023-2028
4. Global PD-1 and PD-L1 Inhibitors Historical Market: Breakup by Application (USD Billion), 2018-2022
5. Global PD-1 and PD-L1 Inhibitors Market Forecast: Breakup by Application (USD Billion), 2023-2028
6. Global PD-1 and PD-L1 Inhibitors Historical Market: Breakup by End User (USD Billion), 2018-2022
7. Global PD-1 and PD-L1 Inhibitors Market Forecast: Breakup by End User (USD Billion), 2023-2028
8. Global PD-1 and PD-L1 Inhibitors Historical Market: Breakup by Region (USD Billion), 2018-2022
9. Global PD-1 and PD-L1 Inhibitors Market Forecast: Breakup by Region (USD Billion), 2023-2028
10. North America PD-1 and PD-L1 Inhibitors Historical Market: Breakup by Country (USD Billion), 2018-2022
11. North America PD-1 and PD-L1 Inhibitors Market Forecast: Breakup by Country (USD Billion), 2023-2028
12. Europe PD-1 and PD-L1 Inhibitors Historical Market: Breakup by Country (USD Billion), 2018-2022
13. Europe PD-1 and PD-L1 Inhibitors Market Forecast: Breakup by Country (USD Billion), 2023-2028
14. Asia Pacific PD-1 and PD-L1 Inhibitors Historical Market: Breakup by Country (USD Billion), 2018-2022
15. Asia Pacific PD-1 and PD-L1 Inhibitors Market Forecast: Breakup by Country (USD Billion), 2023-2028
16. Latin America PD-1 and PD-L1 Inhibitors Historical Market: Breakup by Country (USD Billion), 2018-2022
17. Latin America PD-1 and PD-L1 Inhibitors Market Forecast: Breakup by Country (USD Billion), 2023-2028
18. Middle East and Africa PD-1 and PD-L1 Inhibitors Historical Market: Breakup by Country (USD Billion), 2018-2022
19. Middle East and Africa PD-1 and PD-L1 Inhibitors Market Forecast: Breakup by Country (USD Billion), 2023-2028
20. Global PD-1 and PD-L1 Inhibitors Market Structure
Key Questions Answered in the Report
In 2021, the global PD-1 and PD-L1 inhibitors market attained a value of nearly USD 30.3 billion.
The market is projected to grow at a CAGR of 17.50% between 2023 and 2028.
The market is estimated to witness a healthy growth in the forecast period of 2023-2028 to reach a value of USD 80.9 billion by 2027.
The major drivers of the industry, such as the increased demand for efficient cancer treatment solutions, rising geriatric population, changing consumer lifestyles, growing awareness pertaining to cancer treatments, and increased investments by the governments to support the healthcare and pharmaceutical industries, are expected to aid the industry growth.
The key market trends guiding the growth of the industry include the rising incidences of cancer worldwide.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The different types include PD-1 inhibitors and PD-L1 inhibitors.
The significant applications include Hodgkin lymphoma, kidney cancer, melanoma, non-small cell lung cancer, and others.
The significant end users include hospital pharmacies, retail pharmacies, and online pharmacies.
The major players in the industry are F. Hoffmann-La Roche AG, Sanofi S.A., Amgen Inc., AstraZeneca PLC, Pfizer Inc., Bristol-Myers Squibb Company, and others.
Analyst Review
The global PD-1 and PD-L1 inhibitors market attained a value of USD 30.3 billion in 2021, driven by the rising incidences of cancer. Aided by the growing geriatric population and favourable government initiatives, the market is expected to witness a further growth in the forecast period of 2023-2028, growing at a CAGR of 17.50%. The market is projected to reach USD 80.9 billion by 2027.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. By type, the market can be distributed into PD-1 inhibitors and PD-L1 inhibitors. On the basis of application, the industry can be segmented into Hodgkin lymphoma, kidney cancer, melanoma, non-small cell lung cancer, and others. Based on end user, the market can be categorised into hospital pharmacies, retail pharmacies, and online pharmacies. The major regional markets for PD-1 and PD-L1 inhibitors are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include F. Hoffmann-La Roche AG, Sanofi S.A., Amgen Inc., AstraZeneca PLC, Pfizer Inc., Bristol-Myers Squibb Company, and others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$1699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$2799-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$3999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
NEWSLETTER